ADJUVANT CAPITAL
Adjuvant Capital is a life sciences investment firm focused on global health. The company makes $10-$25 million investments in ambitious companies targeting opportunities in high burden and neglected disease. Adjuvant Capital was founded in 2012 by Charlie Petty, Glenn Rockman, and Kabeer Aziz and is based in New York.
ADJUVANT CAPITAL
Industry:
Financial Services Health Care Venture Capital
Founded:
2012-01-01
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon WordPress Apache Wordpress Plugins Euro Microsoft Exchange Online
Current Advisors List
Current Employees Featured
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-02-16 | Memo Therapeutics | Adjuvant Capital investment in Series B - Memo Therapeutics | 23 M CHF |
| 2022-01-07 | Curevo | Adjuvant Capital investment in Series A - Curevo | 60 M USD |
| 2021-11-02 | Antiva Biosciences | Adjuvant Capital investment in Series D - Antiva Biosciences | 31 M USD |
| 2021-09-16 | 54gene | Adjuvant Capital investment in Series B - 54gene | 25 M USD |
| 2021-07-07 | VitriVax | Adjuvant Capital investment in Series A - VitriVax | N/A |
| 2021-05-27 | Pulmocide | Adjuvant Capital investment in Series C - Pulmocide | 92 M USD |
| 2021-02-24 | Yisheng Biopharma | Adjuvant Capital investment in Series B - Yisheng Biopharma | 130 M USD |
| 2021-02-17 | Excision BioTherapeutics | Adjuvant Capital investment in Venture Round - Excision BioTherapeutics | 60 M USD |
| 2021-02-03 | Frontier Nutrition | Adjuvant Capital investment in Series B - Frontier Nutrition | 6 M USD |
| 2021-02-02 | Excision BioTherapeutics | Adjuvant Capital investment in Series A - Excision BioTherapeutics | N/A |